Licensed

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically meaningful improvements in certain clinical outcome assessments, including physical...